Parkinson disease, L-dopa, and neuropathy Did we miss something?

被引：5
|
作者：
Tison, Francois [1 ,2 ,3 ]
Le Masson, Gwendal [2 ,4 ]
机构：
[1] CHU Bordeaux, Serv Neurol, GH Sud, Hop Haut Leveque, F-33604 Pessac, France
[2] Bordeaux Univ, Bordeaux, France
[3] CNRS, Inst Malad Neurodegenerat, UMR 5293, Bordeaux, France
[4] INSERM 862, Inst Francois Magendie, Bordeaux, France
来源：
NEUROLOGY | 2011年 / 77卷 / 22期
关键词：
HOMOCYSTEINE LEVELS; LEVODOPA;
D O I：
10.1212/WNL.0b013e31823de107
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1938 / 1939
页数：2
相关论文
共 50 条
  • [21] Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease
    Blandini, F
    Fancellu, R
    Martignoni, E
    Mangiagalli, A
    Pacchetti, C
    Samuele, A
    Nappi, G
    CLINICAL CHEMISTRY, 2001, 47 (06) : 1102 - 1104
  • [22] L-DOPA: A scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski, Janusz
    Nistico, Robert
    Berretta, Nicola
    Guatteo, Ezia
    Bernardi, Giorgio
    Mercuri, Nicola B.
    PROGRESS IN NEUROBIOLOGY, 2011, 94 (04) : 389 - 407
  • [23] L-dopa impairs associative learning in Parkinson's disease
    Shohamy, D
    Myers, CE
    Onlaor, S
    Gluck, MA
    JOURNAL OF COGNITIVE NEUROSCIENCE, 2002, : 84 - 84
  • [24] Parkinson's disease: Progression and mortality in the L-DOPA era
    DiRocco, A
    Molinari, SP
    Kollmeier, B
    Yahr, MD
    PARKINSON'S DISEASE, 1996, 69 : 3 - 11
  • [25] MEASURING L-DOPA IN PLASMA AND URINE TO MONITOR THERAPY OF ELDERLY PATIENTS WITH PARKINSON DISEASE TREATED WITH L-DOPA AND A DOPA DECARBOXYLASE INHIBITOR
    DUTTON, J
    COPELAND, LG
    PLAYFER, JR
    ROBERTS, NB
    CLINICAL CHEMISTRY, 1993, 39 (04) : 629 - 634
  • [26] The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease
    Heikkinen, H
    Nutt, JG
    LeWitt, PA
    Koller, WC
    Gordin, A
    CLINICAL NEUROPHARMACOLOGY, 2001, 24 (03) : 150 - 157
  • [27] Conversion of L-dopa to Extended Release L-dopa (Rytary®) in Patients with Fluctuating Parkinson's Disease: Predictors of Dose
    Ondo, William
    Coss, Pablo
    Christie, Melissa
    Pascual, Belen
    JOURNAL OF PARKINSONS DISEASE, 2019, 9 (01) : 153 - 156
  • [28] Animal models of Parkinson's disease and L-dopa induced dyskinesia: How close are we to the clinic?
    Lane, Emma
    Dunnett, Stephen
    PSYCHOPHARMACOLOGY, 2008, 199 (03) : 303 - 312
  • [29] Animal models of Parkinson’s disease and L-dopa induced dyskinesia: How close are we to the clinic?
    Emma Lane
    Stephen Dunnett
    Psychopharmacology, 2008, 199 : 303 - 312
  • [30] Did We Miss Something? Correspondence Analysis of Usability Data
    Zabramski, Stanislaw
    Stuerzlinger, Wolfgang
    HUMAN-COMPUTER INTERACTION - INTERACT 2013, PT IV, 2013, 8120 : 272 - 279
12345